Amivantamab (Rybrevant®) is indicated for the treatment of adult patients with advanced NSCLC with activating EGFR Exon 20 insertion mutations, after failure of platinum-based therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||17/01/2022|
|Rapid review completed||03/02/2022|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of amivantamab compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by the HSE||23/02/2022|
|Pre-submission consultation with Applicant||28/03/2022|
|Current Status||Awaiting HTA submission from Applicant|